CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 13, 2018--
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical
company developing novel medicines to treat life-altering central
nervous system (CNS) disorders, today announced that the company will
host a conference call and live webcast on Thursday, February 22, 2018
at 8:00 A.M. ET to report its fourth quarter and full year 2017
financial results and to discuss recent business updates.
The live webcast can be accessed on the investor page of Sage's website
at investor.sagerx.com. The conference call can be accessed by dialing
1-866-450-8683 (toll-free domestic) or 1-281-542-4847 (international)
and using the conference ID 6272049. A replay of the webcast will be
available on Sage's website approximately two hours after the completion
of the event and will be archived for up to 30 days.
About Sage Therapeutics
Sage Therapeutics is a clinical-stage biopharmaceutical company
committed to developing novel medicines to transform the lives of
patients with life-altering central nervous system (CNS) disorders. Sage
has a portfolio of novel product candidates targeting critical CNS
receptor systems, GABA and NMDA. Sage's lead program, a proprietary IV
formulation of brexanolone (SAGE-547), has completed two Phase 3
clinical trials in postpartum depression. Sage is developing its next
generation modulators, including SAGE-217 and SAGE-718, in various CNS
disorders. For more information, please visit www.sagerx.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180213005284/en/
Source: Sage Therapeutics
Sage Therapeutics
Investor Contact:
Paul Cox,
617-299-8377
paul.cox@sagerx.com
or
Media
Contact:
Maureen L. Suda, 585-355-1134
maureen.suda@sagerx.com